seed
Stage
1
Investors
About
Outrun Therapeutics is a preclinical biotech using E3 ligase inhibition to unlock the therapeutic potential of protein stabilisation for the treatment of cancer and other diseases. Its proprietary platform has generated multiple programmes, with the lead programme being a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours.
Explore Outrun Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.